Our Science
Our Approach
Defined Bacterial Consortia
Product Engine
Manufacturing
Intellectual Property
Scientific Insights
Publications
Pipeline & Programs
Pipeline
VE202
VE303
VE707
Commitment to Patients
Our Focus
How It Works
Disease Areas
Inflammatory Bowel Disease
C. difficile
Infection
Clinical Trials
Trials
COLLECTiVE202
RESTORATiVE303
Expanded Access Policy
Who We Are
Company
Mission
Leadership
Team
Board of Directors
Scientific Advisory Board
Partnerships
Careers
Working at Vedanta
Open Positions
News
Press Releases
Our Science
Defined Bacterial Consortia
Product Engine
Manufacturing
Intellectual Property
Publications
Pipeline & Programs
Pipeline
VE202
VE303
VE707
Commitment to Patients
How It Works
Inflammatory Bowel Disease
C. difficile
Infection
Trials
COLLECTiVE202
RESTORATiVE303
Expanded Access Policy
Who We Are
Mission
Leadership
Team
Board of Directors
Scientific Advisory Board
Partnerships
Working at Vedanta
Open Positions
News
Press Releases
Press Releases
Year
All
2025
2024
2023
2022
October 16, 2024
Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes
July 23, 2024
Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
May 21, 2024
Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
April 30, 2024
Vedanta Biosciences Awarded $3.9 Million from CARB-X to Ready VE707 for First-in-Human Study for Prevention of Multidrug-Resistant Infections
April 29, 2024
Vedanta Biosciences to Present at Upcoming Investor Conferences
March 6, 2024
Vedanta Biosciences to Host Investor Meetings at the Leerink Partners 2024 Global Biopharma Conference
Load More
Sorry, nothing found in this query
